NRXP

Announcements

Nothing here yet

Daily updates

• FDA reclassified NRx Pharmaceuticals' preservative-free ketamine ANDA amendment as minorSep 16, 2026

FDA designations

• sdsOct 19, 2026
• NRx Pharmaceuticals Files Patent Application for NRX-100, its Preservative-Free IV Ketamine Formulation for Suicidal DepressionMay 6, 2025

News

• NRx Pharmaceuticals completes manufacturing process validation and confirms two-year stability of preservative-free ketamineOct 19, 2026
• NRx Pharmaceuticals receives an FDA labeling review letter for its preservative-free ketamine productOct 15, 2026
• NRx Defense Systems, an NRx company, receives an $11 million DARPA prime contract to evaluate robotic magnetic stimulation combined with NRX-101 for treatment-resistant depressionSep 30, 2026
• NRx Pharmaceuticals reported that the FDA revised its previous major amendment classification to a minor amendment for preservative-free ketamineSep 16, 2026
• GeNeuro, an NRx Pharmaceuticals company, was awarded European patent rights for GNK-301, a novel ALS drug candidateSep 14, 2026